

GERONTOLOGY AND GERIATRICS

UDC 616-053.9

Prevalence of vitamin D deficiency in elderly people with sarcopenia in the north-west of Russia*Yu. A. Safonova, E. G. Zotkin, G. M. Glazunova*North-Western State Medical University named after I. I. Mechnikov,
41, ul. Kirochnaya, St. Petersburg, 191015, Russian Federation**For citation:** Safonova Yu. A., Zotkin E. G., Glazunova G. M. Prevalence of vitamin D deficiency in elderly people with sarcopenia in the north-west of Russia. *Vestnik of Saint Petersburg University. Medicine*, 2019, vol. 14, issue 1, pp. 58–68. <https://doi.org/10.21638/11701/spbu10.2019.107>

Vitamin D deficiency is quite common and highly prevalent in some regions of the world, seriously compromising quality of elderly people life. Optimal vitamin D level in serum is associated with stronger muscles and indicates additional 4–11 % improvement of muscular performance and 17 % risk reduction of elderly people falls. Increased risk of falls due to sarcopenia is strongly associated with such undesirable health outcomes as disability, institutionalization, and eventually death. This study analyzes vitamin D status in 69 elderly people with sarcopenia among 230 participants (96.5 % of women, mean age of 74.1 ± 6.5 years), equaling to 30 % (8.7 % in men, 91.3 % in women) prevalence in this age group. For evaluation of sarcopenia level, EWGSOP criteria were used. Muscle strength was assessed by a handheld dynamometer and muscle functioning was evaluated by SPPB-tests (walking speed, Five-Times-Sit-to-Stand-Test and standing balance). Insufficient vitamin D supply was found in 97 % of subjects with sarcopenia and 85.8 % — without sarcopenia. Optimal vitamin D levels were identified only in 3 % of sarcopenic subjects and 14.2 % of non-sarcopenic ones with $p < 0.01$. Mean Vitamin 25 (OH) D level in general population constituted 19.6 ± 5.44 ng/ml. Mean vitamin D level among sarcopenic subjects aged 65–84 years constituted 18.2 ± 3.04 ng/ml, while among older individuals aged 85+ years — 15.1 ± 6.43 ng/ml, $p > 0.05$. History of falls within 12 months prior to the study was reported in 89.9 % of patients with sarcopenia. Among them vitamin D deficiency was found in 60.3 % (95 % CI: 53.0–67.4, $\chi^2 = 8.81$ with $p = 0.012$). 85.8 % of individuals with vitamin D deficiency had low muscle strength ($\chi^2 = 174.61$, $p < 0.001$). 60.4 % of participants with sarcopenia and vitamin D deficiency had low total SPPB score (CI: 45.3–74.2, $p < 0.05$). Obtained data is indicative of high vitamin D deficiency prevalence. It was found out that Sarcopenia increases risk of vitamin D deficiency by 1.2 times (RR 1.2, 95 % CI: 1.06–1.36, $p < 0.01$) in all studied age groups.

Keywords: vitamin D prevalence, vitamin D level, elderly, sarcopenia.

1. Introduction

High prevalence of vitamin D deficiency in different populations of different world regions was proved in numerous surveys [1–3]. Lack and deficiency of 25(OH)D appeared to be more common in older age groups [4], causing variety of symptoms and major health consequences in the most vulnerable elderly population [5–8]. Large number of investigations revealed strong correlation between vitamin D deficiency and increased risk of falls and fractures [9; 10], but also associated with comorbide states, such as cardiovascular diseases, malignant neoplasms, neuropsychic disorders, infections, and autoimmune diseases [11–15]. Meta-analysis of cohort studies demonstrated beneficial effect of continuous vitamin D intake on reducing overall mortality, mostly among aged less 80 years [16; 17]. It was found out that serum levels of vitamin 25 (OH) D less than 10 ng/l are associated with lower muscle strength due to sarcopenia, leading to balance disorders, falls and fractures in the elderly [5; 18–20].

Russia currently launched a few long-term studies to assess the prevalence of vitamin D deficiency in general population, with special focus on the age group > 65 years [21–23]. This report provides data from the populational study conducted in the North-West of Russia, as a part of Nationwide program, with a special focus on 25 (OH) D deficiency in sarcopenic subjects aged > 65 years.

2. Materials and methods

2.1. Study of presented sampled participants

All study participants were recruited from a geriatric doctor based on the following inclusion criteria: residents of the community, age ≥ 65 years, adequate physical functioning and absence of any conditions compromising it; able to move around without walking aid, and absence of cognitive impairment based on total score of Mini mental state examination (MMSE).

Exclusion criteria were as follows: nursing home residence, use of hormone replacement and/or psychotropic drugs, cerebrovascular diseases, severe decompensated heart and renal diseases, non-controlled malignancies, neurological or psychiatric disorders, any kind of dizziness, blurred vision or lightheadedness when rising or standing for long time, indicative of orthostatic hypotension and/or vestibular disorders.

All the patients signed informed consent statement prior to inclusion into the study.

2.2. Definitions of sarcopenia

All 230 participants in the study were subjected to anthropometric evaluation (height and weight, body mass index — BMI). Following EWGSOP criteria, the diagnosis of sarcopenia was based on Dual Energy X-ray (DXA HOLOGIC Explorer QDR) measurement of skeletal muscle mass index (SMI) defined as appendicular skeletal mass/height² (kg/m²). Handgrip strength was evaluated by handheld dynamometer (HDD), and muscle function was assessed using Short Physical Performance Battery (SPPB) tests (evaluating balance, gait, side-by-side together in semi-tandem and tandem positions, time to walk 4 meters to pass at the usual speed and time to rise from a chair and return to the seated position five times).

2.3. Assessment blood samples

Blood samples were collected in cold weather conditions (from September to May) from 179 patients, and serum was stored at -70°C . Serum 25-hydroxyvitamin D (25 (OH) D) was measured using chemiluminescent immunoassay, ng/ml (Abbott Architect, USA). Vitamin D and Calcium intake was forbidden within 12 months prior to enrolment.

Vitamin D status was evaluated in accordance with Endocrine society criteria (ENDO, 2011) [26], which are also used by Central European Endocrine associations [27]. Vitamin D deficit was diagnosed at 25 (OH) D level in serum less than 20 ng/mL, insufficiency of vitamin D — at level equal 20–29 ng/mL, and sufficiency of vitamin D — at level over 30 ng/mL.

2.4. Statistic analysis

Skeletal muscle mass index cut off values $< 5.45 \text{ kg/m}^2$ for women and $< 7.26 \text{ kg/m}^2$ for men were used for establishing the clinical diagnosis of sarcopenia. Handgrip strength was evaluated by using handheld dynamometer (HDD). The test values were considered low based on thresholds $< 20 \text{ kg}$ for women, and $< 30 \text{ kg}$ for men. Muscle function was assessed using Short Physical Performance Battery (SPPB) tests (evaluating balance, gait, strength and endurance by examining an individual's ability to stand with the feet side-by-side together in semi-tandem and tandem positions, time to walk 4 meters to pass at the usual speed and time to rise from a chair and return to the seated position five times). The SPPB test total score was calculated by summarizing individual scores per task using a standardized 0 to 12 scale. The total SPPB score ≤ 9 was considered low. Vitamin D status was assessed according to the Endocrine Society criteria (ENDO, 2011) [26], which are also used by the Central European Endocrinology Associations [27]. Vitamin D deficiency was diagnosed at serum 25(OH)D levels $< 20 \text{ ng/ml}$, insufficiency — 20–29 ng/ml levels, and sufficiency $\geq 30 \text{ ng/ml}$.

The level of significance was 5 % ($p < 0.05$) and all the analyses were conducted using soft ware STATISTICA for Windows (version 10 of BXXR310F964808FA-V). All the data were presented as mean value \pm standard deviation (SD). Comparison of frequency distributions of qualitative variables was assessed by nonparametric χ^2 test. Comparison of quantitative variables was performed using ANOVA. Pearson correlation was used to find the correlation between analysed variables.

3. Results

3.1. Original Patient Characteristics

230 patients aged > 65 years (222 women — 96.5% and 8 men — 3.5%), mean age 74.1 ± 6.5 years, living at latitude northern 59° and at Eastern longitude 35° . Based on the sarcopenia status all participants were divided into two major groups: sarcopenic older adults ($n = 69$) and non-sarcopenic older adults ($n = 161$). The total study population was broken into 3 age groups: A-group include people aged 65–74 years, group B — 75–84 years, group C — patients older than 85 years. Analysis of studied population revealed, that sarcopenia prevalence increases with patients age and at the age 85 years and older were revealed rather frequently ($p < 0.01$). Obesity and metabolic syndrome are seldom revealed with statistical significance among patients with sarcopenia ($p < 0.0001$). Male

gender possesses increased risk of sarcopenia ($p = 0.01$). It is natural, that prevalence of sarcopenia increases with age, with the number of sarcopenic individuals prevailing the number of non-sarcopenic in group C ($p < 0.01$). Low and normal BMI values increase the risk of sarcopenia ($p < 0.0001$). Individuals from both — sarcopenic and non-sarcopenic groups — had similar educational levels, living standards, smoking status, and disability status (Table 1).

Table 1. Characteristics of studied group

Characteristics	Sarcopenic older adults (n = 69)	Non-sarcopenic older adults (n = 161)	P-value
Age, years [mean (\pm SD)]	75.9 (6.8)	73.1 (6.1)	0.0023
65–74 y [n (%)]	24 (34.8)	88 (54.7)	0.0057
75–84 y	36 (52.2)	65 (40.4)	0.098
≥ 85 y	9 (13.0)	8 (5.0)	0.032
Sex [n (%)]			
Women	63 (91.3)	159 (98.8)	0.010
Men	6 (8.7)	2 (1.2)	
Disability	50 (72.5)	117 (72.7)	0.97
Single-living people	29 (42.0)	73 (45.3)	0.64
Smoking status [n (%)]			
Never	65 (94.2)	157 (97.5)	0.25
Former	4 (5.8)	4 (2.5)	
Prevalent disease [n (%)]			
Cardiovascular disease	50 (72.5)	121 (75.2)	0.69
Metabolic syndrome	6 (8.7)	80 (49.7)	< 0.0001
Obesity	2 (2.9)	65 (40.4)	< 0.0001
Chronic Obstructive Pulmonary Diseases	4 (5.8)	13 (8.1)	0.54
Diabetes	4 (5.8)	16 (9.9)	0.31

3.2. Vitamin D provision

Serum vitamin 25 (OH) D levels were measured for 179 patients (66 with sarcopenia and 113 without sarcopenia) among 230 elderly patients. Measured vitamin 25 (OH) D concentration varied from 2.3 to 70.5 ng/mL. Mean (\pm SD) vitamin D level constituted 19.6 ± 5.44 ng/ml in studied samples of 179 patients, 17.8 ± 8.6 ng/ml — in sarcopenic, and 20.7 ± 5.44 ng/ml — in non-sarcopenic ($p = 0.016$). Therefore, based on the Endocrine Society criteria (ENDO, 2011) and Central European Guidelines [27], vitamin D deficiency was revealed in 60.3% (95% CI: 53,0–67,4, $\chi^2 = 8,81$, $p = 0.012$), vitamin D insufficiency—in 29.6% and vitamin D sufficiency — in only 10.1% out of 179 examined patients (Table 2).

Optimal vitamin 25 (OH) D level (vitamin D level ≥ 30 ng/mL) was found only in 3% of sarcopenic patients and in 14.2% of non-sarcopenic ones.

Among 179 patient evaluated mean vitamin 25 (OH) D levels in group A (aged 65 to 74 years; n = 83: 80 F/3 M) constituted 20.3 ± 7.71 ng/mL, in group B (aged 75 to 84 years;

Table 2. Prevalence of vitamin D deficiency and insufficiency in the studied population and groups with and without sarcopenia

Serum 25 (OH)D levels	Sarcopenic older adults (n = 66)		Non-sarcopenic older adults (n = 113)		Overall (n = 179)		p*
	Abs.,(%)	95 % CI	Abs.,(%)	95 % CI	Abs.,(%)	95 % CI	
<20 ng/ml	48 (72.7)	61.2–82.9	60 (53.1)	43.8–62.3	108 (60.3)	53.0–67.4	0.012
20 to 29 ng/ml	16 (24.2)	14.6–35.4	37 (32.7)	24.3–41.7	53 (29.6)	23.1–36.5	
≥ 30 ng/ml	2 (3.0)	0.3–8.6	16 (14.2)	8.3–21.2	18 (10.1)	6.1–14.9	

* — Fisher's criterion.

n = 85: 81 F/4 M) — 19.3 ± 15.9 ng/mL, in group C (aged >85 years; n = 11: 11 F/0 M) — 16.7 ± 6.43 ng/mL ($p < 0.05$). Gender M/F differences in mean vitamin D levels in 3 analysed age groups were as follows: group A — 14.5 ± 2.47 ng/ml vs 20.6 ± 7.71 ng/ml ($p < 0.01$), and group B — 15.5 ± 4.1 ng/ml vs 19.5 ± 4.21 ng/ml ($p < 0.05$).

Comparison of mean serum 25 (OH) D levels in 3 age groups in relation to sarcopenia status is presented in Fig. 1.

Mean vitamin 25 (OH) D values in group A in relation to sarcopenia were as follows: in subjects with sarcopenia (n = 23: 21 F/2 M) 18.2 ± 3.04 ng/ml, and without sarcopenia (n = 60: 59 F/1 M) — 21.1 ± 1.63 ng/ml ($p < 0.05$); in group B in sarcopenic subjects (n = 35: 31 F/4 M) 17.9 ± 1.45 ng/ml, in non-sarcopenic (n = 50: 50 F/0 M) — 20.2 ± 1.63 ng/ml ($p < 0.01$), in group C — sarcopenic (n = 8: 8 F/0 M) — 15.1 ± 1.63 ng/ml, and non-sarcopenic (n = 3: 3 F/0 M) — 20.9 ± 1.23 ng/ml ($p < 0.01$)

Vitamin D deficiency was revealed among all men regardless of their sarcopenia status. As for female population, vitamin 25 (OH) D deficiency (<20 ng/ml) was detected in 70 % of patients with sarcopenia and 52.7 % without sarcopenia, vitamin 25 (OH) D insufficiency (20–29 ng/ml) was found in 26.7 % sarcopenic females and 33 % non-sarcopenic, while optimal vitamin 25 (OH) D levels (≥ 30 ng / ml) present only in 3.3 % of sarcopenic women and in 14.3 % — non-sarcopenic ($p < 0.01$) (Fig. 2).

3.3. Vitamin D and skeletal muscles

Analysis of skeletal muscle parameters was carried out in relation to vitamin 25(OH) D levels (see Table 3).

Multivariate analysis showed lower mean handgrip strength values in vitamin D deficient (< 20 ng / mL) patients, equaling to 15.5 ± 4.3 kg, as compared to individuals with sufficient vitamin D levels — 22.6 ± 4.7 kg ($p < 0.001$). Mean gait speed in vitamin D deficient patients constituted 0.63 ± 0.16 m/s, while in case of patients with sufficient vitamin D level — 0.84 ± 0.12 m/s. SPPB mean score in vitamin D deficient cases was 7.1 ± 2.4 points, and in case of vitamin D sufficient patients — 10.1 ± 1.6 points. 85.8 % patients with vitamin D deficit had low handgrip strength ($\chi^2 = 174.61$, $p < 0.001$). And 60.4 % of participants with sarcopenia and vitamin D deficit had low total SPPB score (95 % CI: 45.3–74.2, $p < 0.05$).




Fig. 1. Mean serum 25 (OH) D levels in sarcopenic and non-sarcopenic patients in 3 studied age groups.




Fig. 2. Prevalence of vitamin D deficiency and its insufficiency in performed study among men and women with and without sarcopenia.

Table 3. Correlation of serum 25(OH)D level with skeletal muscles parameters

Parameters	Serum 25 (OH) D levels, ng/ml, Me [Q1; Q3]			P [^]	Serum 25 (OH) D levels, ng/ml (M±σ)			Overall (n = 230)	P [*]
	≥ 30 (n = 18)	20 to 29 (n = 53)	<20 (n = 108)		≥ 30 (n = 18)	20 to 29 (n = 53)	<20 (n = 108)		
Handgrip strength, kg	22.0 [20.0; 25.0]	18.0 [15.0; 19.0]	15.0 [13.0; 18.0]	<0.001	22.6±4.7	17.0±3.9	15.5±4.3	17.0±4.8	<0.001
Gait speed, m/s	0.85 [0.80; 0.91]	0.71 [0.61; 0.80]	0.64 [0.4; 0.76]	<0.001	0.84±0.2	0.70±0.18	0.63±0.16	0.69±0.18	<0.001
SPPB score, point	10.0 [10.0; 11.0]	9.0 [7.0; 10.0]	7.0 [6.0; 9.0]	<0.001	10.1±1.6	8.0±2.6	7.1±2.4	7.8±2.6	<0.001

[^] — Mann-Whitney U test; ^{*} — Welch test.

4. Discussion

Sarcopenia is a common clinical problem for people aged over 65 years, associated with many unfavorable outcomes [28]. The prevalence of sarcopenia varies widely, depending on specific population studied (such as community residents, or people living in nursing or care homes in respective environment, or different social and ethnic groups, or geography of residence, etc.) [29; 30] and differences in the methods used to evaluate muscle mass, handgrip strength and physical performance. A number of factors are known to affect muscle strength and muscle function with aging, and the relationship between skeletal muscle health and vitamin D levels has been well documented in clinical studies [32; 33]. A wide range of muscle deficiencies associated with varying degrees of vitamin D deficiency has been described, as well as positive effects of vitamin D supplementation.

The study was aimed to determine prevalence of the patients with sarcopenia among residents at North-West of Russia. Sarcopenia was assessed following the EWGSOP guidelines; therefore the procedure included evaluation of the index of muscle mass, skeletal muscle strength and physical performance [24]. The prevalence of sarcopenia in the population assessed equaled to 30.0%. According to the International Sarcopenia Initiative Report (ISI, 2014), the prevalence of sarcopenia varies significantly, with inevitable regional and age-related fluctuations, and achieving 1–29% levels — among community residents, 14–33% — in long-term care groups, and 10% — in a single acute hospital care survey. These data were collected from eighteen documents that were finally selected by members of the ISI working group for inclusion into this review [30]. Prevalence of sarcopenia in the Russian northwestern cohort was higher, than in other countries. Presumably this difference can be explained by some socio-economic (desolated single elderly people, monotonous diet, sedentary life styles) and environmental factors (insufficient sunlight). A more sophisticated analysis produced quite expected results: higher prevalence of sarcopenia among elderly aged 85+ years. Multiple studies confirmed increasing with age prevalence of sarcopenia [34; 35]. Prevalence of sarcopenia among studied three age groups (A: 65–74, B: 75–84, C: 85 years and older), reached 21.4%, 35.6% and 52.9%, respectively.

Clinical relationship between serum vitamin D concentrations and muscle strength/physical characteristics was determined in many observational studies. In the Invecchiare in Chianti study (InCHIANTI) (966 individuals, 435 men and 531 women; mean age 75 years), significant correlation between low vitamin D levels and poor physical performance was established using a hand grip test and a short physical battery test. Physical performance of patients with serum vitamin D below 25 nmol/L was lower than in case of patients with vitamin level above 25 nmol/L. The handgrip muscle strength based on obtained high precision dynamometry data was also significantly higher in case of individuals with vitamin D levels above 50 nmol/L as compared to patients whose level was lower this threshold [36]. Mastaglia et al. reported higher lower limbs muscular strength of women over 65 years with vitamin D levels greater than 50 nmol/L [37]. A meta-analysis of seven studies showed that participants receiving low doses of vitamin D or placebo had baseline muscle strength between 3 and 23 kg [38]. In detailed analysis of data from the prospective study of Longitudinal Aging in Amsterdam (LASA) (1200 elderly men and women, 3 years follow up), Visser et al. showed that elderly people with low vitamin D levels (< 25 nmol/L) had 2.5-fold increased risk of sarcopenia, defined as a loss of more

than 40 % of the arm strength or loss of more than 3 % muscle mass over a 3-year period compared to patients with vitamin D levels over 50 nmol/L [39]. Bischoff-Ferrari et al. in a survey of the US outpatient population aged 60–90 years (n = 4100) showed that 25 (OH) D concentrations between 40 and 94 nmol/L are associated with an improvement in the function of lower extremities musculoskeletal system, than concentrations < 40 nmol/L [40]. The older population is heterogeneous in age and related frailty due to varying prevalence of chronic diseases and types of treatment, and also with respect to dependence in daily life activities. Therefore, it can be expected, that studies involving the elderly will yield in general mixed results unless the population is defined more accurately according to above mentioned factors. Moreover, the gender issue should be taken into account, as most studies recruited only or predominantly women.

Our results are consistent with many published reports, indicating strong association between vitamin D level and muscular status and performance. There's an obvious trend of deteriorating with age vitamin D deficiency/insufficiency, leaving only 10,1 % of studied population with vitamin D sufficiency. This cross-sectional study established a direct association between vitamin D status and parameters of muscle strength and physical performance. Hence, handgrip strength, gait speed, and total SPPB score were significantly lower in subjects with serum 25(OH)D levels < 20 ng/ml as compared to individuals with normal vitamin D concentrations. Mean 25(OH)D levels were significantly lower among women with established sarcopenia vs subjects without sarcopenia in all age groups (65–75, 76–85, >85 years old): 18.2 ± 3.04 vs. 21.1±1.63 ng/ml; 17.9±1.45 vs. 20.2±1.63 ng/ml, and 15.1±1.63 vs. 20.9±1.23 ng/ml respectively.

5. Conclusion

Preliminary data from survey of elderly people living in the North-West region of the Russian Federation show close relationship between vitamin D status and muscular strength and function. Provided evidence indicate that vitamin D deficiency is associated with a decrease in muscle strength and function. Studies with sufficient sample size and more sophisticated analyses are needed to identify more precisely the prevalence and risk factors for sarcopenia.

Transparency declaration. The lead author affirms that this paper is an honest, accurate and transparent account of the study being reported, that no important aspects of the study have been omitted.

Acknowledgements: none.

Declarations of interest: none.

Conflict of interest, source of funding and Authorship

The authors declare that they have no conflicts of interest.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

1. Van Schoor N. M., Lips P. Worldwide vitamin D status. *Best Practice & Research Clinical Endocrinology & Metabolism*, 2011, vol. 25, no. 4, pp. 671–680. <https://doi.org/10.1016/j.beem.2011.06.007>

2. Lips P. Vitamin D status and nutrition in Europe and Asia. *The Journal of Steroid Biochemistry and Molecular Biology*, 2007, vol. 103, no. 3–5, pp. 620–625. <https://doi.org/10.1016/j.jsbmb.2006.12.076>
3. Bruyère O., Slomian J., Beaudart C., Buckinx F., Cavalier E., Gillain S., Petermans J., Reginster J. Y. Prevalence of vitamin D inadequacy in European women aged over 80 years. *Archives of Gerontology and Geriatrics*, 2014, vol. 59, no. 1, pp. 78–82. <https://doi.org/10.1016/j.archger.2014.03.010>
4. Holick M. F. Vitamin D deficiency. *N. Engl. J. Med.*, 2007, vol. 357, no. 3, pp. 266–281. <https://doi.org/10.1056/nejmra070553>
5. Wacker M., Holick M. F. Vitamin D — Effects on skeletal and extraskeletal health and the need for supplementation. *Nutrients*, 2013, vol. 5, no. 1, pp. 111–148. <https://doi.org/10.3390/nu5010111>
6. Gendelman O., Itzhaki D., Makarov S., Bennun M., Amital H. A randomized double-blind placebo-controlled study adding high dose vitamin D to analgesic regimens in patients with musculoskeletal pain. *Lupus*, 2015, vol. 24, no. 4–5, pp. 483–489. <https://doi.org/10.1177/0961203314558676>
7. Heath K. M., Elovic E. P. Vitamin D deficiency—Implications in the rehabilitation setting. *Am. J. Phys. Med. Rehab.*, 2006, vol. 85, no. 11, pp. 916–923. <https://doi.org/10.1097/01.phm.0000242622.23195.61>
8. Shinchuk L., Holick M. F. Vitamin D and rehabilitation: Improving functional outcomes. *Nutr. Clin. Pract.*, 2007, vol. 22, no. 3, pp. 297–304. <https://doi.org/10.1177/0115426507022003297>
9. The DIPART Group. Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. *BMJ*, 2010, no. 340, p. b5463. <https://doi.org/10.1136/bmj.b5463>
10. Bolland M. J., Grey A., Gamble G. D., Reid I. R. The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. *Lancet Diab. Endocrinol.*, 2014, vol. 2, no. 4, pp. 307–320. [https://doi.org/10.1016/s2213-8587\(13\)70212-2](https://doi.org/10.1016/s2213-8587(13)70212-2)
11. Pourshahidi L. K. Vitamin D and obesity: current perspectives and future directions. *Proceedings of the Nutrition Society*, 2014, vol. 74, no. 2, pp. 115–124. <https://doi.org/10.1017/s0029665114001578>
12. Antico A., Tampoia M., Tozzoli R., Bizzaro N. Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. *Autoimmunity Reviews*, 2012, vol. 12, no. 2, pp. 127–136. <https://doi.org/10.1016/j.autrev.2012.07.007>
13. Seida J. C., Mitri J., Colmers I. N., Majumdar S. R., Davidson M. B., Edwards A. L., Hanley D. A., Pittas A. G., Tjosvold L., Johnson J. A. Effect of Vitamin D Supplementation on Improving Glucose Homeostasis and Preventing Diabetes: A Systematic Review and Meta-Analysis. *J. Clin. Endocrinol. Metab.*, 2014, vol. 99, no. 10, pp. 3551–3560. <https://doi.org/10.1210/jc.2014-2136>
14. Souberbielle J. C., Body J. J., Lappe J. M., Plebani M., Shoenfeld Y., Wang T. J., Bischoff-Ferrari H. A., Cavalier E., Ebeling P. R., Fardellone P., Gandini S., Gruson D., Guérin A. P., Heickendorff L., Hollis B. W., Zittermann A. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. *Autoimmunity Reviews*, 2010, vol. 9, no. 11, pp. 709–715. <https://doi.org/10.1016/j.autrev.2010.06.009>
15. Lavie C. J., Lee J. H., Milani R. V. Vitamin D and cardiovascular disease will it live up to its hype? *J. Am. Coll. Cardiol.*, 2011, vol. 58, no. 15, pp. 1547–1556. <https://doi.org/10.1016/j.jacc.2011.07.008>
16. Zheng Y., Zhu J., Zhou M., Cui L., Yao W., Liu Y. Meta-Analysis of Long-Term Vitamin D Supplementation on Overall Mortality. Meta-Analysis of Long-Term Vitamin D Supplementation on Overall Mortality. *PLoS ONE*, 2013, vol. 8, no. 12, p. e82109. <https://doi.org/10.1371/journal.pone.0082109>
17. Kalyani R. R., Stein B., Valiyil R., Manno R., Maynard J. W., Crews D. C. Vitamin D treatment for the prevention of falls in older adults: systematic review and meta-analysis. *J. Am. Geriatr. Soc.*, 2010, vol. 58, no. 7, pp. 1299–1310. <https://doi.org/10.1111/j.1532-5415.2010.02949.x>
18. Bruyère O., Cavalier E., Souberbielle J. C., Bischoff-Ferrari H. A., Beaudart C., Buckinx F., Reginster J. Y., Rizzoli R. Effects of vitamin D in the elderly population: current status and perspectives. *Archives of Public Health*, 2014, vol. 72, no. 1, p. 32. <https://doi.org/10.1186/2049-3258-72-32>
19. Bischoff-Ferrari H. A. Relevance of vitamin D in muscle health. *Rev. Endocr. Metab. Disord*, 2012, vol. 13, no. 1, pp. 71–77. <https://doi.org/10.1007/s11154-011-9200-6>
20. Beaudart C., Buckinx F., Rabenda V., Gillain S., Cavalier E., Slomian J., Petermans J., Reginster J. Y., Bruyère O. The Effects of Vitamin D on Skeletal Muscle Strength, Muscle Mass, and Muscle Power: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *J. Clin. Endocrinol. Metab.*, 2014, vol. 99, no. 11, pp. 4336–4345. <https://doi.org/10.1210/jc.2014-1742>
21. Bakhtiarova S., Lesnyak O., Kuznetsova N., Blankenstein M. A., Lips P. Vitamin D status among patients with hip fracture and elderly control subjects in Yekaterinburg, Russia. *Osteoporoz. Int.*, 2006, vol. 17, no. 3, pp. 441–446. <https://doi.org/10.1007/s00198-005-0006-9> (In Russian)
22. Karonova T. L., Grineva E. N., Nikitina I. L., Tsvetkova E. V., Todieva A. M., Beliaeva O. D., Mikheeva E. P., Globa P. Yu., Andreeva A. T., Beletskaya I. S., Omelchuk N. V., Fulonova L. S., Shlyakhto E. V. Prevalence of vitamin D deficiency in the North-West region of the Russian Federation among residents of St.

- Petersburg and Petrozavodsk. *Osteoporoz i osteopatii*, 2013, vol.16, no.3, pp.33–37. <https://doi.org/10.14341/osteo201333-7> (In Russian)
23. Safonova Yu.A., Zotkin E.G., Glazunova G.M., Strukov E.L. Analysis of security by vitamin D of the elderly people. *Adv. geront.*, 2018, vol.31, no.2, pp.184–190. (In Russian)
 24. Cruz-Jentoft A.J., Baeyens J.P., Bauer J.M., Boirie Y., Cederholm T., Landi, F., Martin F.C., Michel J.-P., Rolland Y., Schneider S.M., Topinkova E., Vandewoude M., Zamboni M. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. *Age and Ageing*, 2010, vol. 39, no. 4, pp.412–423. <https://doi.org/10.1093/ageing/afq034>
 25. Cruz-Jentoft A.J., Bahat G., Bauer J., Boirie Y., Bruyère O., Cederholm T., Cooper C., Landi, F., Rolland Y., Sayer A.A., Schneider S.M., Sieber C.C., Topinkova E., Vandewoude M., Visser M., Zamboni M. Sarcopenia: revised European consensus on definition and diagnosis. *Age and Ageing*, 2019, vol. 48, no. 1, pp.16–31. <https://doi.org/10.1093/ageing/afy169>
 26. Holick M.F., Binkley N.C., Bischoff-Ferrari H.A., Gordon C.M., Hanley D.A., Heaney R.P., Heaney R.P., Hassan Murad M., Weaver C.M. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. *J. Clin. Endocrinol. Metab.*, 2011, vol.96, no. 7, pp.1911–1930. <https://doi.org/10.1210/jc.2011-0385>
 27. Pludowski P., Karczmarewicz E., Bayer M., Carter G., Chlebna-Sokół D., Czech-Kowalska J., Dębski R., Decsi T., Dobrzańska A., Franek E., Głuszko P., Grant W.B., Holick M.F., Yankovskaya, Konstantynowicz J., Książyk J.B., Książopolska-Orłowska K., Lewiński A., Litwin M., Lohner S., Lorenc R.S., Łukaszkiwicz J., Marcinowska-Suchowierska E., Milewicz A., Misiorowski W., Nowicki M., Povoroznyuk V., Rozentryt P., Rudenka E., Shoenfeld Y., Socha P., Solnica B., Szalecki M., Tałałaj M., Varbiro S., Żmijewski M. A. Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe — recommendation of vitamin D intakes in the general population and groups at risk of vitamin D deficiency. *Endokrynol. Pol.*, 2013, vol. 64, no. 4, pp.319–327. <https://doi.org/10.5603/ep.2013.0012>
 28. Fielding R. A., Vellas B., Evans W. J., Bhasin S., Morley J. E., Newman A. B., Gabor van Kan A., Andrieu S., Bauer J., Breuille D., Cederholm T., Chandler J., C. De Meynard, Donini L., Harris T., Kannt A., Guibert F.K., Onder G., Papanicolaou D, Rolland Y., Rooks D., Sieber C., Souhami E., Verlaan S., Zamboni M. Prevalence, Etiology, and Consequences. International Working Group on Sarcopenia. *Journal of the American Medical Directors Association*, 2011, vol. 12, no. 4, pp.249–256. <https://doi.org/10.1016/j.jamda.2011.01.003>
 29. Iannuzzi-Sucich M., Prestwood K.M., Kenny A. M. Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women. *J. Gerontol. A. Biol. Sci. Med. Sci.*, 2002, vol. 57, no. 12, pp. M772–777. <https://doi.org/10.1093/gerona/57.12.m772>
 30. Cruz-Jentoft A.J., Landi F., Schneider S.M., Zuniga C., Arai H., Boirie Y., Chen L-K., Fielding R. A., Martin F.C., Michel J.-P., Sieber C., Stout J.R., Studenski S.A., Vellas B., Woo J., Zamboni M., Cederholm T. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). *Age and Ageing*, 2014, vol. 43, no. 6, pp.748–759. <https://doi.org/10.1093/ageing/afu115>
 31. Espinel-Bermúdez M. C., Ramírez-García E., García-Peña C., Salvà-Casanovas A., Ruiz-Arregui L., Cárdenas-Bahena A., Sánchez-García S. Prevalence of sarcopenia in community-dwelling older people of Mexico City using the EWGSOP (European Working Group on Sarcopenia in Older People) diagnostic criteria. *J. Cachexia, Sarcopenia and Muscle*, 2017, vol.2, no.2, pp.12–17. <https://doi.org/10.17987/jcsm-cr.v2i2.9>
 32. Boland R. Role of vitamin D in skeletal muscle function. *Endocr. Rev.*, 1986, vol. 7, no. 4, pp.434–448. <https://doi.org/10.1210/edrv-7-4-434>
 33. Fougère B., Vellas B., van Kan G. A., Cesari M. Identification of biological markers for better characterization of older subjects with physical frailty and sarcopenia. *Transl. Neurosci.*, 2015, vol. 6, no. 1, pp.103–110. <https://doi.org/10.1515/tnsci-2015-0009>
 34. Volpato S., Bianchi L., Cherubini A., Landi F., Maggio M., Savino E., Bandinelli S., Ceda G.P., Guralnik J.M., Zuliani G., Ferrucci L. Prevalence and clinical correlates of sarcopenia in community-dwelling older people: application of the EWGSOP definition and diagnostic algorithm. *J. Gerontol. A. Biol. Sci. Med. Sci.*, 2014, vol. 69, no. 4, pp.438–446. <https://doi.org/10.1093/gerona/glt149>
 35. Gariballa S., Alessa A. Sarcopenia: prevalence and prognostic significance in hospitalized patients. *Clin Nutr.*, 2013, vol. 32, no. 5, pp.772–776. <https://doi.org/10.1016/j.clnu.2013.01.010>
 36. Houston D.K., Cesari M., Ferrucci L., Cherubini A., Maggio D., Bartali B., Johnson M.A., Schwartz G.G., Kritchevsky S.B. Association between vitamin D status and physical performance:

the InCHIANTI study. *Journals of Gerontology Series A: Biological Sciences and Medical Sciences*, 2007, vol. 62, no. 4, pp. 440–446. <https://doi.org/10.1093/gerona/62.4.440>

37. Mastaglia S.R., Seijo M., Muzio D., Somoza J., Nunez M., Oliveri B. Effect of vitamin D nutritional status on muscle function and strength in healthy women aged over sixty-five years. *Journal of Nutrition, Health and Aging*, 2011, vol. 15, no. 5, pp. 349–354. <https://doi.org/10.1007/s12603-010-0287-3>
38. Rosendahl-Riise H., Spielau U., Ranhoff A.H., Gudbrandsen O.A., Dierkes J. Vitamin D supplementation and its influence on muscle strength and mobility in community-dwelling older persons: a systematic review and metaanalysis. *J. Hum. Nutr. Diet.*, 2017, vol. 30, no. 1, pp. 3–15. <https://doi.org/10.1111/jhn.12394>
39. Visser M.D., Deeg D.J.H., Lips P. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. *Journal of Clinical Endocrinology and Metabolism*, 2003, vol. 88, no. 12, pp. 5766–5772. <https://doi.org/10.1210/jc.2003-030604>
40. Bischoff-Ferrari H.A., Dietrich T., Orav E.J., Hu F.B., Zhang Y., Karlson E.W., Dawson-Hughes B. Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged ≥ 60 y. *Am. J. Clin. Nutr.*, 2004, vol. 80, no. 3, pp. 752–758. <https://doi.org/10.1093/ajcn/80.3.752>

Received: October 16, 2018

Accepted: December 3, 2018

Author's information:

Yuliya A. Safonova — PhD, Associate Prof.; jula_safonova@mail.ru

Evgeny G. Zotkin — MD; ezotkin@mail.ru

Galina M. Glazunova — g-glazunova@mail.ru